A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE)

Dd, Gladman; Urowitz, MB; Ong, Anthony D.; Gough, J; Mackinnon, Anne

doi:10.1177/096120339600500305

Cited by 80 publications

(64 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have confirmed this in the current study (Figure 1). Many studies have found no correlation between the SF-36 and disease activity (12,15,16). Others have found a relationship between the SF-36 and disease activity using the Systemic Lupus Activity Measure, or British Isles Lupus Assessment Group (18,24,25).…”

Section: Discussionmentioning

confidence: 99%

“…However, inconsistent results have been reported regarding the influence of disease activity and damage on quality of life. Some studies have demonstrated a lack of correlation among these outcomes while others have shown disease variables to be strong predictors of quality of life (12)(13)(14)(15)(16)(17)(18). A recent review of quality of life in SLE concluded that there was no correlation with disease activity or damage (19).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Quality of life over time in patients with systemic lupus erythematosus

Kuriya¹,

Gladman²,

Ibanez³

et al. 2008

Arthritis & Rheumatism

134

108

View full text Add to dashboard Cite

Objective. To determine whether quality of life in patients with systemic lupus erythematosus (SLE) measured by the Short Form 36 (SF-36) changes over time and which patient-and disease-related factors influence such change. Methods. SLE patients who had >6 SF-36 evaluations during followup were identified from a database. Outcomes were slopes of scores of the 8 SF-36 domains as well as the physical and mental component scores. Based on the direction of the slope, patients were designated as unchanged, improved, or worsened. Linear regression models were used to test the contribution of risk factors to slopes. Nonparametric tests were used to evaluate risk factors between patterns of clinical change. Results. A total of 146 patients had >6 SF-36 evaluations in 1,047 visits over a mean ؎ SD period of 8.2 ؎ 1.1 years. During the interval, the majority of patients showed no change in the SF-36 domains and only a small minority demonstrated improvement. Physical and mental component scores were unchanged in 84.3% and 87.7% of patients whereas 4.1% and 7.5% improved, respectively. According to slopes of the domains and summary scores, only physical functioning demonstrated a significant decrease over time. There were no lupus disease features associated with decline in physical functioning except for the presence of fibromyalgia. Conclusion. The SF-36 in SLE patients with established disease changed little over an 8-year period. Changes in the SF-36 were not affected by disease activity, steroids, or damage accumulation during the interval, but were affected by the presence of fibromyalgia.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Quality of life over time in patients with systemic lupus erythematosus

Kuriya¹,

Gladman²,

Ibanez³

et al. 2008

Arthritis & Rheumatism

134

108

View full text Add to dashboard Cite

show abstract

“…It has been recommended as the instrument to measure quality of life in patients with SLE by the Systemic Lupus International Collaborating Clinics Group (SLICC) [1]. The SF-36 is a valid and reliable tool that identifies the physical, psychological, and social influence of the disease on patients with SLE [4,5]. However, longitudinal studies that assessed HRQoL of patients with SLE have shown that SF-36 is not sensitive to change when administered biannually or yearly [6,7].…”

Section: Introductionmentioning

confidence: 99%

Health-related quality of life assessed by LupusQoL questionnaire and SF-36 in Turkish patients with systemic lupus erythematosus

et al. 2015

View full text Add to dashboard Cite

The LupusQoL is a disease-specific health-related quality of life (HRQoL) measure for patients with lupus. We conducted this study to compare the efficiency of LupusQoL-TR (validated Turkish version of the LupusQoL questionnaire) with the 36-item Short-Form Health Survey (SF-36), a generic quality of life (QoL) scale, in Turkish patients with lupus. Both questionnaires were conducted at a single visit to the clinic. Disease activity was measured with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Associations between the LupusQoL-TR and SF-36 domains were examined while also examining age, disease duration, and disease activity for each questionnaire. Descriptive statistics, Spearman's correlation coefficients, and Students t test were performed to analyze the data. A total of 113 consecutive patients with lupus (F/M 108:5, mean age 40.6 ± 11.9 years, mean disease duration 8.5 ± 7.0 years) were included, and 69 % of these were active. The median SLEDAI score was 2 (0-24), the mean global LupusQoL-TR score was 60.9 ± 23.3, and the mean SF-36 score was 41.2 ± 9.0. There was a significant correlation between LupusQoL-TR and SF-36 mean scores (r = 0.83; p < 0.001). QoL assessed by LupusQoL-TR and SF-36 did not correlate with disease activity (r = -0.11; p = 0.244 and r = -0.03; p = 0.721, respectively). LupusQoL-TR and SF-36 questionnaires were beneficial instruments in evaluating HRQoL in Turkish lupus patients. However, LupusQoL-TR and SF-36 were not associated with SLEDAI scores, which suggested that QoL might be affected by other factors besides disease activity, especially in clinically inactive or mildly active patients.

show abstract

“…Das schränkt eine Bewertung über serologische Parameter wesentlich ein. Und schließlich gibt es mit der Erkrankung assoziierte Symptome, wie die häufige Abgeschlagenheit (Fatigue), die offenbar oft nicht mit der Krankheitsaktivität gekoppelt ist [18,27,32,46] und deren Genese nicht ausreichend erforscht erscheint [33]. …”

unclassified

Systemischer Lupus erythematodes: Aktivität und Outcome

Aringer

Smolen

2006

Z Rheumatol

View full text Add to dashboard Cite

Both clinically and scientifically, the variable organ manifestations of systemic lupus erythematosus (SLE) pose a particular challenge to rheumatologists. Validated scores for disease activity (BILAG, ECLAM, SIS, SLAM, SLEDAI), damage (SLICC/ACR damage index) and health-related quality of life (MOS SF-36) have been successfully used for years. New therapies, however, need to show improvement on outcome parameters for defined organ systems--and these are mostly ill-defined. For proliferative lupus nephritis, well designed studies have been available for years. However, these use very severe outcome parameters (renal failure, death), and therefore take at least 5 years for definitive results. Of the surrogate markers which were devised, none has proven reliable for determining outcome. The combination of shorter studies for defining hopeful strategies followed by long definitive studies, appears to be the best option at present.

show abstract

A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE)

Cited by 80 publications

References 13 publications

Quality of life over time in patients with systemic lupus erythematosus

Quality of life over time in patients with systemic lupus erythematosus

Health-related quality of life assessed by LupusQoL questionnaire and SF-36 in Turkish patients with systemic lupus erythematosus

Systemischer Lupus erythematodes: Aktivität und Outcome

Contact Info

Product

Resources

About